The study aimed to evaluate the safety and effectiveness of an investigational drug in relieving moderate to severe migraine attacks.
Acute Migraine
Hightower Clinical previously participated in a study evaluating an investigational drug for moderate to severe migraine. The goal was to bring faster and more effective relief to patients experiencing acute episodes.
Evaluated a New Approach for Treating Migraine Pain
Migraines are intense headaches often accompanied by nausea, sensitivity to light and sound, and vision changes. They can significantly disrupt daily activities and lower the quality of life. Acute migraine treatment is essential for reducing the severity and duration of an attack.
To identify more effective treatment options, Hightower Clinical conducted a study evaluating an investigational drug. The study aimed to assess the safety and efficacy of the drug across multiple dose ranges in patients experiencing moderate to severe migraine episodes.
Current Status
Not Recruiting
Study Count
01
Study Information
Acute Migraine
| Study Name | Protocol Number | Sponsor |
|---|---|---|
| Acute Migraine | KAL-AGT01-007 | Alnylam |
Frequently Asked Questions
2. Who participated in the study?
Adults who experienced moderate to severe migraines were enrolled to assess the potential benefits of the study drug.
3. Is this clinical trial still enrolling patients?
No, the trial is currently not recruiting new participants.
Unlock New Opportunities in Clinical Research - Join Today!
We're here and eager to assist. Reach out to Hightower Clinical Research in Oklahoma City, OK for further details on how we can support you.
Get Involved Today!
© Copyright 2024 – Hightower Clinical. CREATED BY DIGITAL AUXILIUS.